Seelos Therapeutics Statistics
Total Valuation
Seelos Therapeutics has a market cap or net worth of 215,799. The enterprise value is 10.08 million.
| Market Cap | 215,799 |
| Enterprise Value | 10.08M |
Important Dates
The next estimated earnings date is Friday, March 7, 2025.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Seelos Therapeutics has 435,958 shares outstanding. The number of shares has increased by 191.24% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 435,958 |
| Shares Change (YoY) | +191.24% |
| Shares Change (QoQ) | +54.70% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 10.31% |
| Float | 433,823 |
Valuation Ratios
The trailing PE ratio is 0.01.
| PE Ratio | 0.01 |
| Forward PE | n/a |
| PS Ratio | 0.02 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 2.46 |
| EV / Sales | 5.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.08
| Current Ratio | 0.08 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -278.58 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -261.11% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 251,750 |
| Profits Per Employee | 511,375 |
| Employee Count | 16 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.90% in the last 52 weeks. The beta is 1.94, so Seelos Therapeutics's price volatility has been higher than the market average.
| Beta (5Y) | 1.94 |
| 52-Week Price Change | -99.90% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 32.71 |
| Relative Strength Index (RSI) | 30.55 |
| Average Volume (20 Days) | 22,302 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Seelos Therapeutics had revenue of 2.01 million and earned 4.09 million in profits. Earnings per share was 47.06.
| Revenue | 2.01M |
| Gross Profit | -18.44M |
| Operating Income | -29.81M |
| Pretax Income | 4.09M |
| Net Income | 4.09M |
| EBITDA | n/a |
| EBIT | -29.81M |
| Earnings Per Share (EPS) | 47.06 |
Balance Sheet
The company has 294,000 in cash and 10.16 million in debt, giving a net cash position of -9.86 million or -22.62 per share.
| Cash & Cash Equivalents | 294,000 |
| Total Debt | 10.16M |
| Net Cash | -9.86M |
| Net Cash Per Share | -22.62 |
| Equity (Book Value) | -28.13M |
| Book Value Per Share | -135.50 |
| Working Capital | -28.18M |
Cash Flow
| Operating Cash Flow | -13.27M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,480.04% |
| Pretax Margin | 203.13% |
| Profit Margin | 203.13% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Seelos Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -191.24% |
| Shareholder Yield | -191.24% |
| Earnings Yield | 9,507.13% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on September 27, 2024. It was a reverse split with a ratio of 0.0625.
| Last Split Date | Sep 27, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0625 |
Scores
Seelos Therapeutics has an Altman Z-Score of -202.9. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -202.9 |
| Piotroski F-Score | n/a |